Covid-19: Critically ill patients treated with arthritis drug tocilizumab show improved outcomes, researchers report

J Wise - 2020 - bmj.com
J Wise
2020bmj.com
The rheumatoid arthritis drug tocilizumab seems to improve outcomes in patients with covid-
19 who are the most severely ill, show early results released from the Remap-Cap
international platform trial.The researchers reported that critically ill patients receiving
tocilizumab were more likely to improve than patients who received no immune modulator
(odds ratio 1.87).“These are very exciting and encouraging results,” said the chief
investigator, Anthony Gordon, consultant in intensive care medicine at Imperial College …
The rheumatoid arthritis drug tocilizumab seems to improve outcomes in patients with covid-19 who are the most severely ill, show early results released from the Remap-Cap international platform trial.
The researchers reported that critically ill patients receiving tocilizumab were more likely to improve than patients who received no immune modulator (odds ratio 1.87).“These are very exciting and encouraging results,” said the chief investigator, Anthony Gordon, consultant in intensive care medicine at Imperial College Healthcare NHS Trust, at a Science Media Centre briefing on 19 November.
bmj.com